Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Files to Raise up to $46M in Public Offering

NEW YORK (GenomeWeb News) – Cancer Genetics has filed to raise up to $46 million in a public offering of its stock.

The company, which went public in April, filed its Form S-1 with the US Securities and Exchange Commission on Tuesday. It has not priced its shares or said how many shares it plans to offer. In August, Cancer Genetics made a public offering of $15 million of its shares, and began trading on the Nasdaq.

Aegis is listed as the sole book-running agent on Tuesday's SEC filing.

During the second quarter, the Rutherford, NJ-based cancer diagnostics firm said revenues increased 64 percent year over year to $1.8 million. It ended the quarter with $1.9 million in cash and cash equivalents.

In afternoon trading shares of Cancer Genetics were down more than 17 percent at $15.51.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.